|
|
|
| Preparation and immunizing dose analysis of inactivated hepatitis A vaccine using attenuated H2 strain |
| LI Hongsen1, PING Ling1,2, WANG Zhengxin1, JIANG Houfei1, HOU Dinglin1, ZHANG Yirong1, WANG Lingxi1, YANG Jingsi1,2
|
1. Institute of Medical Biology, Peking Union Medical College, Chinese Academy of Medical Sciences, Kunming, Yunnan 650118, China;
2. Kunming Science and Technology Innovation Center for R&D and Industrialization of Emerging Highly Pathogenic Pathogen Vaccines, Kunming, Yunnan 650118, China |
|
|
|
|
Abstract Objective To prepare an inactivated hepatitis A vaccine using a attenuated strain of hepatitis A virus (HAV) H2 and to analyze its immunizing dose, so as to provide the reference for development and production of inactivated hepatitis A vaccines. Methods Human embryonic lung diploid cells (KMB17) were infected with attenuated HAV H2 strain to proliferate the virus, then the cells containing viruses were harvested, extracted and purified. The obtained virus concentrate was prepared into vaccine bulk and test vaccines with 1 280 EU/mL antigen content. Vaccine testing was carried out according to the inactivated hepatitis A vaccine standards specified in the Part Ⅲ of the Pharmacopoeia of the People's Republic of China (2020 edition). A total of 110 mice were randomly divided into 11 groups, including 5 dose groups (80, 160, 320, 640 and 1 280 EU/dose) of the test vaccine and the reference vaccine, as well as the adjuvant control group. Mice were immunized twice by intraperitoneal injection, their serum HAV antibodies were detected, and the geometric mean titer (GMT) and positive conversion rate of antibodies were analyzed to evaluate the immunising dose of the vaccine. Results The antigen content and viral titer of the virus harvest solution were 5 120 EU/mL and 8.33 lgCCID50/mL, respectively. The removal rate of foreign protein reached 98.05% and the recovery rate of antigen was 66.25%. The test vaccine met the requirements of Part Ⅲ of the Pharmacopoeia of the People's Republic of China (2020 edition). The GMTs of HAV antibodies in the test vaccine and the reference vaccine dose groups after the second immunization were more than twice higher than those after the first immunization. Regardless of primary immunization or secondary immunization, the GMTs (log2) of HAV antibodies in the test vaccine groups with doses of 160 EU/dose and above were higher than those in the 80 EU/dose group (all P<0.05), while there was no statistically significant differences between the dose groups of 160 EU/dose and above (all P>0.05). The antibody positive conversion rate of 160 EU/dose and above of the test vaccine was 100.00% after the secondary immunization. Conclusions The inactivated hepatitis A vaccine of attenuated H2 strain tested in this study demonstrates strong immunogenicity in mice, suggesting its potential as a candidate vaccine. The preliminary analysis indicates an immunizing dose of 320 EU/dose for children and 640 EU/dose for adults.
|
|
Received: 19 February 2024
Revised: 17 April 2024
Published: 17 May 2024
|
|
|
|
|
|
[1] LIU X L,YANG C L,QU X Q,et al.Vaccination coverage and its determinants of live attenuated hepatitis A vaccine among children aged 24-59 months in 20 rural counties of 10 provinces of China in 2016[J].Hum Vaccin Immunother,2020,16(7):1574-1578.
[2] SU X,ZHENG L,ZHANG H M,et al.Secular trends of acute viral hepatitis incidence and mortality in China,1990 to 2019 and its prediction to 2030:the global burden of disease study 2019[J/OL].Front Med(Lausanne),2022,9[2024-04-17].http://doi.org/10.3389/fmed.2022.842088.
[3] LUO J,WANG X,MA F,et al.Long-term immunogenicity and immune persistence of live attenuated and inactivated hepatitis a vaccines:a report on additional observations from a phase IV study[J].Clin Microbiol Infect,2019,25(11):1422-1427.
[4] 刘建生,侯宗柳,马绍辉,等.甲型肝炎减毒活疫苗H2减毒株P2区基因序列测定与特征分析[J].中国疫苗和免疫,2008,14(1):7-10.
[5] 黄小琴,杨净思,周德久,等.H2株甲肝病毒经KMB17细胞培养的毒力及核苷酸序列[J].中国生物制品学杂志,2000,13(3):133-135.
[6] 黄小琴,练幼辉,王庆龄,等.甲型肝炎减毒活疫苗H2株在狨猴体内传代的实验[J].中华预防医学杂志,1997,31(5):260-262.
[7] 忻亚娟,庄防成,姜立民,等.冻干甲型肝炎减毒活疫苗诱导的人体特异性免疫应答[J].中国生物制品学杂志,2009,22(2):180-182.
[8] BAKKER W A,THOMASSEN Y E,VAN'T OEVER A G,et al.Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV[J].Vaccine,2011,29(41):7188-7196.
[9] 石昊昱,廖国阳,车艳春,等.Sabin株脊髓灰质炎灭活疫苗的研发及应用进展[J].中国生物制品学杂志,2022,35(8):897-906.
[10] 国家药典委员会.中华人民共和国药典(2020年版)[M].北京:中国医药科技出版社,2020.
[11] GEIER D A,JORDAN S K,GEIER M R.The relative toxicity of compounds used as preservatives in vaccines and biologics[J].Med Sci Monit,2010,16(5):21-27.
[12] ATWATER A R,PETTY A J,LIU B,et al.Contact dermatitis associated with preservatives:retrospective analysis of North American contact dermatitis group data 1994-2016[J].J Am Acad Dermatol,2021,84(4):965-976.
[13] VAN DAMME P,VON SONNENBURG F,HATZ C,et al.Long-term immunogenicity of preservative-free hepatitis B vaccine formulations in adults[J].J Med Virol,2009,81(10):1710-1715.
[14] 刘令九,岳立广,徐艳玲,等.甲型肝炎灭活疫苗(L-A-1减毒株)的制备及其免疫原性[J].中国生物制品学杂志,2015,28(1):6-9.
[15] WAGNER R,HILDT E.Composition and mode of action of adjuvants in licensed viral vaccines[J].Bundesgesundheitsbla,2019,62(4):462-471.
[16] SASAKI E,FURUHATA K,MIZUKAMI T,et al.An investigation and assessment of the muscle damage and inflammation at injection site of aluminum-adjuvanted vaccines in guinea pigs[J].J Toxicol Sci,2022,47(11):439-451.
[17] 毛群颖,钟熙,马丽颖,等.甲肝灭活疫苗在不同品系小鼠中的免疫应答效果[C]//中国药学会.2010年中国药学大会暨第十届中国药师周论文集.天津:中国药学会:8438-8442.
[18] 杨二霞,李海巍,封晓菁,等.生产场地变更后甲型肝炎灭活疫苗(人二倍体细胞)的抗原特性[J].中国生物制品学杂志,2016,29(4):337-341.
[19] GONG Q,RUAN M D,NIU M f,et al.Immune efficacy of different immunization doses of divalent combination DNA vaccine pOPRL+pOPRF of Pseudomonas aeruginosa[J].J Vet Med Sci,2021,83(12):1959-1964.
[20] RHODES S J,KNIGHT G M,KIRSCHNER D E,et al.Dose finding for new vaccines:the role for immunostimulation/immunodynamic modelling[J].J Theor Biol,2019,465:51-55.
[21] JUAN-GINER A,KIMATHI D,GRANTZ K H,et al.Immunogenicity and safety of fractional doses of yellow fever vaccines:a randomised,double-blind,non-inferiority trial[J].Lancet,2021,397(10269):119-127.
[22] KORSA M G,DEVLIN J M,HARTLEY C A,et al.Determination of the minimum protective dose of a glycoprotein-G-deficient infectious laryngotracheitis virus vaccine delivered via eye-drop to week-old chickens[J/OL].PLoS One,2018,13[2024-04-17].http://doi.org/10.1371/journal.pone.0207611. |
|
|
|
